Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-KIDNEY
NCT03594110Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of empagliflozin in chronic kidney disease (CKD), sponsored by Boehringer Ingelheim. Started Jan 2019; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03594110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594110.